Intralesional cidofovir for the treatment of recalcitrant periungual warts

McKayla Poppensa David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USAView further author information

Jeremy Davisb Division of Dermatologic Surgery, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USACorrespondence[email protected]
View further author information

References

Coremans G, Snoeck R. Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions. Expert Opin Pharmacother. 2009;10(8):1343–1352.
PubMed Web of Science ®Google Scholar
Anshelevich EE, Barbieri JS, Kovarik CL. Intralesional cidofovir for treatment of recalcitrant warts in both immunocompetent and immunocompromised patients: a retrospective analysis of 58 patients. J Am Acad Dermatol. 2021;84(1):206–207.
PubMed Web of Science ®Google Scholar
Oh BH. Cidofovir intralesional injection for recalcitrant common warts: a comparison with sodium tetradecyl sulfate intralesional injection. Ann Dermatol. 2020;32(4):273–279.
PubMed Web of Science ®Google Scholar
Blouin MM, Cloutier R, Noël R. Intralesional cidofovir in the treatment of cutaneous warts in a renal transplant patient. J Cutan Med Surg. 2012;16(6):462–464.
PubMed Web of Science ®Google Scholar
Broganelli P, Chiaretta A, Fragnelli B, et al. Intralesional cidofovir for the treatment of multiple and recalcitrant cutaneous viral warts. Dermatol Ther. 2012;25(5):468–471.
PubMed Web of Science ®Google Scholar